# ![@TOWiU2 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1132559626065592321.png) @TOWiU2 MASi

MASi posts on X about $hrow, $srpt, $mrkde, $zlab the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1132559626065592321/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1132559626065592321/c:line/m:interactions.svg)

- [--] Week [---------] +4,318%
- [--] Month [---------] +34,568%
- [--] Months [---------] +4,543%
- [--] Year [---------] +5,564%

### Mentions: [--] [#](/creator/twitter::1132559626065592321/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1132559626065592321/c:line/m:posts_active.svg)

- [--] Week [--] +77%
- [--] Month [--] -21%
- [--] Months [---] +58%
- [--] Year [---] +177%

### Followers: [-----] [#](/creator/twitter::1132559626065592321/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1132559626065592321/c:line/m:followers.svg)

- [--] Week [-----] +0.14%
- [--] Month [-----] -0.21%
- [--] Months [-----] +1.70%
- [--] Year [-----] +9.80%

### CreatorRank: [---------] [#](/creator/twitter::1132559626065592321/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1132559626065592321/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  54% [finance](/list/finance)  14% [countries](/list/countries)  3% [technology brands](/list/technology-brands)  1% [travel destinations](/list/travel-destinations)  1%

**Social topic influence**
[$hrow](/topic/$hrow) 15%, [$srpt](/topic/$srpt) #5, [$mrkde](/topic/$mrkde) 12%, [$zlab](/topic/$zlab) 9%, [$mrk](/topic/$mrk) 9%, [$vktx](/topic/$vktx) #31, [$tmo](/topic/$tmo) 7%, [$dhr](/topic/$dhr) 7%, [$srtde](/topic/$srtde) 7%, [ceo](/topic/ceo) 6%

**Top accounts mentioned or mentioned by**
[@biohazard3737](/creator/undefined) [@ltbioinvestor](/creator/undefined) [@hall8jack](/creator/undefined) [@snupsnus](/creator/undefined) [@johnbresnahan](/creator/undefined) [@rnaianalyst](/creator/undefined) [@dorb2sq](/creator/undefined) [@lawbitrage](/creator/undefined) [@jfais20](/creator/undefined) [@dmitrykovalchuk](/creator/undefined) [@merck](/creator/undefined) [@persimmonti](/creator/undefined) [@webcrawlervers](/creator/undefined) [@gjtennis](/creator/undefined) [@judguy](/creator/undefined) [@propthinker](/creator/undefined) [@edcollins23](/creator/undefined) [@stefaanbafort](/creator/undefined) [@imspecter](/creator/undefined) [@yachmod](/creator/undefined)

**Top assets mentioned**
[Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Thermo Fisher Scientific Inc. (TMO)](/topic/$tmo) [Danaher Corporation (DHR)](/topic/$dhr) [Evotec SE (EVO)](/topic/$evo) [Repligen, Corp. (RGEN)](/topic/$rgen) [Halozyme Therapeutics, Inc. (HALO)](/topic/$halo) [Journey Medical Corporation (DERM)](/topic/$derm) [Novavax Inc (NVAX)](/topic/$nvax) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Pfizer, Inc. (PFE)](/topic/$pfe) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Novartis AG (NVS)](/topic/$nvs) [SpringWorks Therapeutics, Inc. Common Stock (SWTX)](/topic/$swtx) [Spruce Biosciences, Inc. (SPRB)](/topic/$sprb) [Synthetify (SNY)](/topic/$sny) [NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)](/topic/$nams) [Inozyme Pharma, Inc. (INZY)](/topic/$inzy) [Novo-Nordisk (NVO)](/topic/$nvo) [Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP)](/topic/$hznp) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Sanofi (SNY)](/topic/sanofi) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [uniQure N.V. (QURE)](/topic/$qure) [Moderna Inc (MRNA)](/topic/$mrna) [Inari Medical, Inc. (NARI)](/topic/$nari)
### Top Social Posts
Top posts by engagements in the last [--] hours

""why no one has come to save us and why no one ever will" https://www.youtube.com/watchv=AHTYiVFe7mI https://www.youtube.com/watchv=AHTYiVFe7mI"  
[X Link](https://x.com/TOWiU2/status/2020915835544457414)  2026-02-09T17:40Z [----] followers, [---] engagements


"Conference Call and Webcast to Discuss Results of Phase 2b REZOLVE-AD Maintenance Data To access the webcast directly please click on the following link to register to join the Zoom webcast: $NKTR https://events.q4inc.com/attendee/811634486 https://ir.nektar.com/news-releases/news-release-details/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate https://events.q4inc.com/attendee/811634486 https://ir.nektar.com/news-releases/news-release-details/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate"  
[X Link](https://x.com/TOWiU2/status/2021201165137084538)  2026-02-10T12:34Z [----] followers, [---] engagements


"$NKTR offering priced at $58 https://finance.yahoo.com/news/nektar-therapeutics-announces-pricing-upsized-032300008.html https://finance.yahoo.com/news/nektar-therapeutics-announces-pricing-upsized-032300008.html"  
[X Link](https://x.com/TOWiU2/status/2021815474405638181)  2026-02-12T05:15Z [----] followers, [---] engagements


"$VKTX $NVO @stnh1116 @MeadowCapital @Pharmdca The quote is from Viking Therapeutics' Q4 [----] earnings call (Feb [--] 2026) where CFO Greg Zante (not CEO Brian Lian as sometimes misattributed) praised Novo Nordisk's oral semaglutide launch (e.g. Rybelsus) as the "fastest in history." It dismisses concerns over the drug's @stnh1116 @MeadowCapital @Pharmdca The quote is from Viking Therapeutics' Q4 [----] earnings call (Feb [--] 2026) where CFO Greg Zante (not CEO Brian Lian as sometimes misattributed) praised Novo Nordisk's oral semaglutide launch (e.g. Rybelsus) as the "fastest in history." It"  
[X Link](https://x.com/TOWiU2/status/2021917252518375609)  2026-02-12T12:00Z [----] followers, [---] engagements


"@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2022432922314375625)  2026-02-13T22:09Z [----] followers, [---] engagements


"RT @BoWang87: A physics textbook says certain particle interactions can't happen. GPT-5.2 said "what if they can under these specific co"  
[X Link](https://x.com/TOWiU2/status/2022484167376642235)  2026-02-14T01:32Z [----] followers, [---] engagements


"$HALO $EVT.DE $EVO #Halozyme CEO: #Evotec Is Poised for Growth https://t.co/R0PBQ84V8u #Halozyme CEO: #Evotec Is Poised for Growth https://t.co/R0PBQ84V8u"  
[X Link](https://x.com/TOWiU2/status/1859504194203304047)  2024-11-21T07:48Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/1997050040976920659)  2025-12-05T21:06Z [----] followers, [---] engagements


"$DERM Clinical Trial Results Assessing the Impact of Emrosi on Microbial Flora of Healthy Adults - achieved all [--] primary objectives w no sig safety issues - can be safely used for up to 16w w no detectable impact on skin GI tract or vaginal microbiota https://ir.journeymedicalcorp.com/new-events/press-releases/detail/100/journey-medical-corporation-announces-publication-of https://ir.journeymedicalcorp.com/new-events/press-releases/detail/100/journey-medical-corporation-announces-publication-of"  
[X Link](https://x.com/TOWiU2/status/1999414510525050967)  2025-12-12T09:42Z [----] followers, [---] engagements


"$DERM https://jddonline.com/articles/impact-of-low-dose-oral-minocycline-dfd-29-on-skin-gastrointestinal-vaginal-microflora-in-healthy-adults-S1545961625P9245X https://jddonline.com/articles/impact-of-low-dose-oral-minocycline-dfd-29-on-skin-gastrointestinal-vaginal-microflora-in-healthy-adults-S1545961625P9245X"  
[X Link](https://x.com/TOWiU2/status/1999414872673575225)  2025-12-12T09:43Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2000328567453069764)  2025-12-14T22:14Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2002317049314312442)  2025-12-20T09:56Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2004661667641348411)  2025-12-26T21:12Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2007357939687043260)  2026-01-03T07:46Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2009739038140281122)  2026-01-09T21:28Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2012487285858517019)  2026-01-17T11:28Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB FINAL UPDATE week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2014815429542240747)  2026-01-23T21:40Z [----] followers, [---] engagements


"FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling $RGNX https://www.fiercebiotech.com/biotech/fda-puts-clinical-hold-regenxbio-gene-therapies-weeks-approval-ruling https://www.fiercebiotech.com/biotech/fda-puts-clinical-hold-regenxbio-gene-therapies-weeks-approval-ruling"  
[X Link](https://x.com/TOWiU2/status/2016792476929974631)  2026-01-29T08:36Z [----] followers, [---] engagements


"$SRPT https://www.neurologylive.com/view/new-3-year-embark-data-highlights-continued-therapeutic-effect-gene-therapy-elevidys-duchenne https://www.neurologylive.com/view/new-3-year-embark-data-highlights-continued-therapeutic-effect-gene-therapy-elevidys-duchenne"  
[X Link](https://x.com/TOWiU2/status/2016850809678364888)  2026-01-29T12:27Z [----] followers, [---] engagements


"26Jan2026 $SRPT joined PPMD [--] discuss recently released 3-year top line data for ELEVIDYS for the treatment of DMD presentation included a review of the data a timely discussion of what this means for the community & next steps as well as a dedicated Q&A https://www.youtube.com/watchv=2rwb6ZSU8Xk https://www.youtube.com/watchv=2rwb6ZSU8Xk"  
[X Link](https://x.com/TOWiU2/status/2018656925429510228)  2026-02-03T12:04Z [----] followers, [----] engagements


"Sarepta Saga Has 'Gone on Too Long' as Competitors Catch Up Would like to invite you all for your honest thoughts on this $SRPT write up from Dan Samorodnitsky at BioSpace. https://www.biospace.com/drug-development/sarepta-saga-has-gone-on-too-long-as-competitors-catch-up https://www.biospace.com/drug-development/sarepta-saga-has-gone-on-too-long-as-competitors-catch-up"  
[X Link](https://x.com/TOWiU2/status/2019330259326231012)  2026-02-05T08:40Z [----] followers, [---] engagements


"@Hall8Jack "Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys according to BMO Capital Markets analysts." https://www.biospace.com/drug-development/regenxbio-fails-to-best-sareptas-elevidys-with-new-data-for-dmd-gene-therapy https://www.biospace.com/drug-development/regenxbio-fails-to-best-sareptas-elevidys-with-new-data-for-dmd-gene-therapy"  
[X Link](https://x.com/TOWiU2/status/2021190716857139214)  2026-02-10T11:53Z [----] followers, [---] engagements


"$SPRB "Walbert most recently served as EVP US Commercial @ $HZNP where she was responsible for driving commercial strat & organizational dev for more than [--] marketed brands across nephrology ophthalmology & rare disease among other therapeutic areas" https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-appoints-proven-pharmaceutical-commercial https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-appoints-proven-pharmaceutical-commercial"  
[X Link](https://x.com/TOWiU2/status/2000671463322399179)  2025-12-15T20:57Z [----] followers, [---] engagements


"$SPRB Secures Up to $50M in Growth Capital from Avenue Capital Initial Funding of $15 Million from the First of Four Tranches Extending Cash Runway into [----] Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-secures-50-million-growth-capital-avenue https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-secures-50-million-growth-capital-avenue"  
[X Link](https://x.com/TOWiU2/status/2009269169502494858)  2026-01-08T14:21Z [----] followers, [----] engagements


"$SRPT to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy Monday Jan. [--] [----] at 8:30 am Eastern Time the Company will host a webcast and conference call https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study"  
[X Link](https://x.com/TOWiU2/status/2015742377986539589)  2026-01-26T11:03Z [----] followers, [----] engagements


"@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2017346958315106512)  2026-01-30T21:19Z [----] followers, [----] engagements


"$SRPT ELEVIDYS +84% FY [----] YOY international = licensed to Roche"  
[X Link](https://x.com/TOWiU2/status/2018254029659242631)  2026-02-02T09:23Z [----] followers, [----] engagements


"After Mortality-Marred Year Sarepta Looks Ahead to Catalyst-Rich [----] https://www.biospace.com/business/after-mortality-marred-year-sarepta-looks-ahead-to-catalyst-rich-2026 https://www.biospace.com/business/after-mortality-marred-year-sarepta-looks-ahead-to-catalyst-rich-2026"  
[X Link](https://x.com/TOWiU2/status/2019645348323447166)  2026-02-06T05:32Z [----] followers, [---] engagements


"@dorb2sQ The careers page of $HROW actually shows only [--] open positions which one could with a little goodwill indeed call 'about [---] open positions' but one should always keep this inaccuracy in mind when hearing Baum talk about future business figures. https://www.harrow.com/careers https://www.harrow.com/careers"  
[X Link](https://x.com/TOWiU2/status/2021146293024805178)  2026-02-10T08:56Z [----] followers, [---] engagements


"In Pursuit of Prevalent Disease: Where the Next Mega-Blockbusters Will Be Built Sustaining growth and driving shareholder returns at the scale of todays large pharma players increasingly requires multiple mega-blockbusters ($5B in annual revenue). https://www.lek.com/insights/hea/global/ei/pursuit-prevalent-disease-where-next-mega-blockbusters-will-be-built https://www.lek.com/insights/hea/global/ei/pursuit-prevalent-disease-where-next-mega-blockbusters-will-be-built"  
[X Link](https://x.com/TOWiU2/status/2021167799498936807)  2026-02-10T10:22Z [----] followers, [---] engagements


""full year [----] Dupixent global net sales increased 26% to $17.8 billion" $REGN $SNY $NKTR https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial"  
[X Link](https://x.com/TOWiU2/status/2021288365593645251)  2026-02-10T18:21Z [----] followers, [---] engagements


"Sanofi appoints Beln Garijo as new CEO after deciding not to renew Hudson's mandate $SNY Does today's announcement by $SNY suggest that Merck KGaA's decision to dismiss Belen Garijo was stupid https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-appoints-beln-garijo-new-ceo-after-deciding-not-renew-current-ceo-hudsons-2026-02-12/ https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-appoints-beln-garijo-new-ceo-after-deciding-not-renew-current-ceo-hudsons-2026-02-12/"  
[X Link](https://x.com/TOWiU2/status/2021855391341326726)  2026-02-12T07:54Z [----] followers, [---] engagements


"RT @cloud_walker200: $vktx now vk2735 is officially the most advanced oral peptide in the clinic as well as the only oral version of GLP-1"  
[X Link](https://x.com/TOWiU2/status/2022273770187042849)  2026-02-13T11:36Z [----] followers, [--] engagements


"Viking Therapeutics Inc. $VKTX Q4 FY2025 earnings call transcript https://finance.yahoo.com/quote/VKTX/earnings/VKTX-Q4-2025-earnings_call-401860.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/quote/VKTX/earnings/VKTX-Q4-2025-earnings_call-401860.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"  
[X Link](https://x.com/TOWiU2/status/2022636398038151545)  2026-02-14T11:37Z [----] followers, [---] engagements


"@Lawbitrage @Biohazard3737 sufficient"  
[X Link](https://x.com/TOWiU2/status/2023029095714759155)  2026-02-15T13:38Z [----] followers, [--] engagements


"@Andre_AGTC Does the deuteration add any useful property at all to the drugs being studied or does it only serve to IP-protect aged molecules If it's all about intellectual property would it even hold up in court if it were challenged $CYBN"  
[X Link](https://x.com/TOWiU2/status/2006102106923548889)  2025-12-30T20:36Z [----] followers, [---] engagements


"@Lawbitrage @Biohazard3737 and is committed to invest even further $VKTX https://cordenpharma.com/articles/press-release-cordenpharma-invests-900-million-euros-in-transformational-peptide-platform-expansion-in-usa-and-europe/ https://cordenpharma.com/articles/press-release-cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-near-basel-switzerland/ https://cordenpharma.com/articles/press-release-cordenpharma-invests-900-million-euros-in-transformational-peptide-platform-expansion-in-usa-and-europe/"  
[X Link](https://x.com/TOWiU2/status/2023038319266046150)  2026-02-15T14:14Z [----] followers, [--] engagements


"@BehaviorFin $NTLA $QURE $SGMO $ADAP/ $ADAPY Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2012490014941135346)  2026-01-17T11:39Z [----] followers, [---] engagements


"$SRPT @TOWiU2 Exciting news for families affected by DMD 💙 The HHS has officially added Duchenne Muscular Dystrophy to the newborn screening panel which means earlier detection and support for our little warriors Learn more about this significant step towards better outcomes in the @TOWiU2 Exciting news for families affected by DMD 💙 The HHS has officially added Duchenne Muscular Dystrophy to the newborn screening panel which means earlier detection and support for our little warriors Learn more about this significant step towards better outcomes in the"  
[X Link](https://x.com/TOWiU2/status/2014373526216593891)  2026-01-22T16:24Z [----] followers, [---] engagements


"$SRPT https://finance.yahoo.com/news/sarepta-announces-positive-topline-three-130000508.html https://t.co/c5xDDi3Wu6 $SRPT to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy Monday Jan. [--] [----] at 8:30 am Eastern Time the Company will host a webcast and conference call https://finance.yahoo.com/news/sarepta-announces-positive-topline-three-130000508.html https://t.co/c5xDDi3Wu6 $SRPT to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy"  
[X Link](https://x.com/TOWiU2/status/2015789932212584578)  2026-01-26T14:12Z [----] followers, [---] engagements


"@SnupSnus @john_bresnahan 1/2) Life Sciences or the picks and shovels of the biotech = in fact a great investment but: Tecan JEOL and Siegfried = really do they even understand: a) the difference between: selling an instrument once and recurring business from each production batch b) CDMO vs F&F"  
[X Link](https://x.com/TOWiU2/status/1487113012020400129)  2022-01-28T17:19Z [----] followers, [--] engagements


"@SnupSnus @john_bresnahan Correction: c) $lonn.sw vs $sfnz.sw = 1/2) b) besides: $207940.KS and BI (in which you cannot invest sorry)"  
[X Link](https://x.com/TOWiU2/status/1487120398068158467)  2022-01-28T17:48Z [----] followers, [--] engagements


"@BiotechAnalysst @Bios_n_Techs Even worse: $pdsb is paying $mrk.de "Under the terms of the agreement Merck KGaA Darmstadt Germany will receive an upfront cash payment of $5 million and will be entitled to up to $11 million in development and regulatory milestone payments . " https://www.globenewswire.com/news-release/2023/01/03/2581989/37149/en/PDS-Biotech-Announces-Exclusive-Global-License-Agreement-for-Investigational-IL-12-Tumor-Targeted-Cytokine-from-Merck-KGaA-Darmstadt-Germany.html"  
[X Link](https://x.com/TOWiU2/status/1610248582518697985)  2023-01-03T12:15Z [----] followers, [---] engagements


"$EVO $EVT.DE Down -30% in German trading today. https://www.evotec.com/en/news/evotec-presents-fiscal-year-2023-results-and-announces-priority-reset-to-focus-on-profitable-growth https://www.evotec.com/en/news/evotec-presents-fiscal-year-2023-results-and-announces-priority-reset-to-focus-on-profitable-growth"  
[X Link](https://x.com/TOWiU2/status/1783050379598483778)  2024-04-24T08:28Z [----] followers, [----] engagements


"@MauriceOnTW @jfais20 @MartinShkreli Answer to 5: CDMO is SBL also known as Samsung Biologics next to Lonza the best you can get for it"  
[X Link](https://x.com/TOWiU2/status/2006835190472273997)  2026-01-01T21:09Z [----] followers, [--] engagements


"@DmitryKovalchuk @RNAiAnalyst @Merck $mrk able to support $nvax via "capacities to mass produce" Stan Erck minute 56:10-57:00 "bags filters & media" part of the coordination challenge & "raw material components in short supply". $tmo $dhr $mrk.de $srt.de $rgen https://edge.media-server.com/mmc/p/ex338sjy https://edge.media-server.com/mmc/p/ex338sjy"  
[X Link](https://x.com/TOWiU2/status/1359831343228723203)  2021-02-11T11:47Z [----] followers, [--] engagements


"@DmitryKovalchuk @RNAiAnalyst @Merck $tmo $dhr $mrk.de $srt.de $rgen Stan Erck $nvax called on cos not 2hoard bags. been really complicated 2work around shortages. We just had a minor breakthrough where we thought we were going 2be out of bags in 1particular facility. 1/2 https://www.benzinga.com/general/biotech/21/02/19699000/shortage-of-giant-sterile-liners-threatens-global-vaccines-rollout-ft https://www.benzinga.com/general/biotech/21/02/19699000/shortage-of-giant-sterile-liners-threatens-global-vaccines-rollout-ft"  
[X Link](https://x.com/TOWiU2/status/1362012461470273536)  2021-02-17T12:14Z [----] followers, [--] engagements


"@DalhiMackle The major suppliers $DHR & $TMO are US companies. Also the relevant part of $MRK.DE = Millipore is US. Only different for $SRT.DE"  
[X Link](https://x.com/TOWiU2/status/1384503627440656384)  2021-04-20T13:46Z [----] followers, [--] engagements


"$MRNA = [--] advantages: 1) $LONN.SW = reliable CMO (vs $NVAX) 2) [--] x g/dose = nABs = VE duration (vs $BNTX / $PFE) Summary: There is some danger in this step. Moderna partners with @rtnarch's National Resilience to make hundreds of millions of vaccine doses. https://t.co/fQyPq9wH6k Moderna partners with @rtnarch's National Resilience to make hundreds of millions of vaccine doses. https://t.co/fQyPq9wH6k"  
[X Link](https://x.com/TOWiU2/status/1435870049177423875)  2021-09-09T07:37Z [----] followers, [--] engagements


"@BertrandBio $UCB.BR $UCBJY $UCBJF "unprecedented multiple external headwinds & difficult macro situation lead [--] upward pressure on costs Updated financial guidance for 2022: Revenue expected in the range of 5.3-5.4b adjusted EBITDA2 in the range 21-22 % of revenue" https://www.ucb.com/stories-media/Press-Releases/article/UCB-updates-financial-guidance-for-2022-while-maintaining-2025-financial-guidance https://www.ucb.com/stories-media/Press-Releases/article/UCB-updates-financial-guidance-for-2022-while-maintaining-2025-financial-guidance"  
[X Link](https://x.com/TOWiU2/status/1540332609384890369)  2022-06-24T13:54Z [----] followers, [--] engagements


"Briumvi vs Ocrevus vs Kesimpta: Understanding Your MS Treatment Options $TGTX $RHHBY $ROG.SW $NVS 1) Administration:"  
[X Link](https://x.com/TOWiU2/status/1737848666323550259)  2023-12-21T14:53Z [----] followers, [----] engagements


"Briumvi vs Ocrevus vs Kesimpta: Understanding Your MS Treatment Options $TGTX $RHHBY $ROG.SW $NVS 2) Clinical Trial Results:"  
[X Link](https://x.com/TOWiU2/status/1737848989205315669)  2023-12-21T14:54Z [----] followers, [----] engagements


"Briumvi vs Ocrevus vs Kesimpta: Understanding Your MS Treatment Options $TGTX $RHHBY $ROG.SW $NVS 3) Source/Link: https://everyone.org/blog/briumvi-vs-ocrevus-vs-kesimpta https://everyone.org/blog/briumvi-vs-ocrevus-vs-kesimpta"  
[X Link](https://x.com/TOWiU2/status/1738104650048373024)  2023-12-22T07:50Z [----] followers, [---] engagements


"$HALO $EVT.DE $EVO https://ir.halozyme.com/news/news-details/2024/Halozyme-Confirms-Proposal-to-Combine-with-Evotec-for-11.00-Per-Share-in-an-All-Cash-Transaction/default.aspx https://ir.halozyme.com/news/news-details/2024/Halozyme-Confirms-Proposal-to-Combine-with-Evotec-for-11.00-Per-Share-in-an-All-Cash-Transaction/default.aspx"  
[X Link](https://x.com/TOWiU2/status/1857336776278315234)  2024-11-15T08:16Z [----] followers, [---] engagements


"@monaco_biotech @Biohazard3737 Should we also see the $HALO bid for $EVO $EVT.DE as part of this particular context"  
[X Link](https://x.com/TOWiU2/status/1857356697284603956)  2024-11-15T09:35Z [----] followers, [---] engagements


"@jfais20 $EVT.DE $EVO Given the $XBI situation (RFKj year-end tax loss sale January debt ceiling etc.) they r not in a bad situation as there r apparently [--] parties trying to buy them $HALO (confirmed) & Triton (rumors but significantly increased share). Plus EBITDA positive 2025"  
[X Link](https://x.com/TOWiU2/status/1858087003415269481)  2024-11-17T09:57Z [----] followers, [---] engagements


"Questions: If $HALO would not succeed in buying $EVO $EVT.DE what should be the market capitalization of an independent Evotec based on a minimum revenue of $790 million and an adjusted EBITDA of at least $15 million (both figures for 2024)"  
[X Link](https://x.com/TOWiU2/status/1859175598846837127)  2024-11-20T10:02Z [----] followers, [----] engagements


"@Sully25259 @OracleNYSE @pnani456 "If successful the acquisition valued at nearly $3 billion would enhance Stryker's capabilities in treating venous thromboembolism." $3 billion probably won't be enough the news/rumors have already brought the $NARI Mcap to $3.7 billion"  
[X Link](https://x.com/TOWiU2/status/1876371539127615541)  2025-01-06T20:53Z [----] followers, [---] engagements


"SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over $SWTX - Educational campaign aims to raise awareness & drive conversation about desmoid tumors - https://finance.yahoo.com/news/springworks-therapeutics-jewelry-designer-jennifer-130000182.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/springworks-therapeutics-jewelry-designer-jennifer-130000182.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"  
[X Link](https://x.com/TOWiU2/status/1892210115714973973)  2025-02-19T13:50Z [----] followers, [---] engagements


"Will be interesting to read the 14D-9 press release is already revealing. $SWTX: "two best-in-class medicines" $MRK.DE: "OGSIVEO (nirogacestat) is a first-in-class therapy" "GOMEKLI (mirdametinib) is the first & only FDA-approved therapy for. adult & pediatric patients""  
[X Link](https://x.com/TOWiU2/status/1916790578030707008)  2025-04-28T09:44Z [----] followers, [----] engagements


"$SRPT will present at the 30th Annual Congress of the World Muscle Society (WMS) [----] Congress taking place Oct. 7-11 [----] in Vienna Austria https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-present-new-data-its-neuromuscular-0 https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-present-new-data-its-neuromuscular-0"  
[X Link](https://x.com/TOWiU2/status/1974787096608145743)  2025-10-05T10:41Z [----] followers, [----] engagements


"$DERM Emrosi vs Oracea: - Enhanced Efficacy - Dual Action on Erythema & Lesions. addressing two annoying symptoms of rosacea - Comparable Safety Profile. However Emrosi had lower discontinuation rates due to adverse events . in some trial arms https://rosacea-support.org/emrosi-what-you-need-to-know.html https://rosacea-support.org/emrosi-what-you-need-to-know.html"  
[X Link](https://x.com/TOWiU2/status/1978001592981807233)  2025-10-14T07:35Z [----] followers, [---] engagements


"Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase [--] Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea $DERM https://www.globenewswire.com/news-release/2025/03/05/3037745/0/en/Journey-Medical-Corporation-Announces-Publication-in-the-Journal-of-the-American-Medical-Association-Dermatology-of-the-Phase-3-Clinical-Trial-Results-of-Emrosi-DFD-29-to-Treat-Ros.html"  
[X Link](https://x.com/TOWiU2/status/1978003355642610024)  2025-10-14T07:42Z [----] followers, [---] engagements


"$DERM Reports Combined Emrosi (DFD-29) Phase [--] Clinical Trial Efficacy Data Analysis DFD-29 demonstrated superior efficacy in IGA success rates & inflammatory lesion counts vs both placebo & doxycycline (P0.001 for all comparisons) https://ir.journeymedicalcorp.com/new-events/press-releases/detail/97/journey-medical-corporation-reports-combined-emrosi https://ir.journeymedicalcorp.com/new-events/press-releases/detail/97/journey-medical-corporation-reports-combined-emrosi"  
[X Link](https://x.com/TOWiU2/status/1983473482202861606)  2025-10-29T09:58Z [----] followers, [---] engagements


"@Biohazard3737 $HROW $ZLAB Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/1994495269728330239)  2025-11-28T19:55Z [----] followers, [---] engagements


"I'm surprised to see that $SWTX didn't even have the lowest biotech buyout premium in [----]. Will the low-payer Merck KGaA ever do anything right Here are the bioturd buyouts from [----] average premium 61%. $xbi https://t.co/7DX0Kvjmvp Here are the bioturd buyouts from [----] average premium 61%. $xbi https://t.co/7DX0Kvjmvp"  
[X Link](https://x.com/TOWiU2/status/2007002418375213501)  2026-01-02T08:13Z [----] followers, [----] engagements


"$DCTH Now Live on OncLive: All [--] ESMO [----] Review Episodes Key Updates in Metastatic Uveal Melanoma https://www.onclive.com/news-network/key-updates-in-metastatic-uveal-melanoma-from-esmo-2025 https://www.onclive.com/news-network/key-updates-in-metastatic-uveal-melanoma-from-esmo-2025"  
[X Link](https://x.com/TOWiU2/status/2009745476413734915)  2026-01-09T21:53Z [----] followers, [---] engagements


"$DCTH Preliminary Fourth Quarter and Full-Year [----] Financial Results (unaudited) revenue approx$20.7m&$85.2m respectively HEPZATO KIT approx$19.0m&$78.8m respectively CHEMOSAT approximately$1.7 millionand$6.4 million respectively https://investors.delcath.com/news-releases/news-release-details/delcath-systems-announces-preliminary-fourth-quarter-and-full-0 https://investors.delcath.com/news-releases/news-release-details/delcath-systems-announces-preliminary-fourth-quarter-and-full-0"  
[X Link](https://x.com/TOWiU2/status/2009746833208209429)  2026-01-09T21:59Z [----] followers, [---] engagements


"$DCTH Recent Business Highlights - Currently [--] active centers - Approximately 140% growth in HEPZATO procedure volume in [----] versus [----] - publications have highlighted the application enhanced outcomes and associated efficacy of percutaneous hepatic perfusion (PHP) "  
[X Link](https://x.com/TOWiU2/status/2009747600312881418)  2026-01-09T22:02Z [----] followers, [---] engagements


"@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week [--] after Poll:"  
[X Link](https://x.com/TOWiU2/status/2012491538404642982)  2026-01-17T11:45Z [----] followers, [---] engagements


"Pfizer Makes $530M Vaccine Play With Novavax Deal After Rumors of BioNTech Pullback $pfe $nvax $bntx https://www.biospace.com/deals/pfizer-makes-530m-vaccine-play-with-novavax-deal-after-rumors-of-biontech-pullback https://www.biospace.com/deals/pfizer-makes-530m-vaccine-play-with-novavax-deal-after-rumors-of-biontech-pullback"  
[X Link](https://x.com/TOWiU2/status/2013770534245306704)  2026-01-21T00:28Z [----] followers, [---] engagements


"@PersimmonTI $MRK.DE finally gets the concept of avidity: "The focus of F-stars platform and the Merck collaboration suggest the molecule will be a tetravalent bispecific antibody against immuno-oncology targets." $AFMD or $PIRS more obvious choice then F-star. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902227/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902227/"  
[X Link](https://x.com/TOWiU2/status/1284943076717461506)  2020-07-19T20:07Z [----] followers, [--] engagements


"@PersimmonTI Maybe I was overoptimistic about $MRK.DE Not sure F-Star understanding of a "tetravalent bispecific antibody" is identical to common definition e.g. $AFMD $PIRS platform designs. Even FS118 was claimed to be "tetravalent bispecific". http://www.f-star.com/pipeline/pipeline-overview/ http://www.f-star.com/pipeline/pipeline-overview/"  
[X Link](https://x.com/TOWiU2/status/1284950096061370374)  2020-07-19T20:35Z [----] followers, [--] engagements


"The comment is not as ridiculous as it may seem at first glance given the poor track record of $mrk.de in drug development. @pawcio2009 Noooo Merck is have such confidence in $PDSB mgmt that they r license drug to them instead of buy them. This is b/c they r knowing it is better in hand of PDSB mgmt. @pawcio2009 Noooo Merck is have such confidence in $PDSB mgmt that they r license drug to them instead of buy them. This is b/c they r knowing it is better in hand of PDSB mgmt"  
[X Link](https://x.com/TOWiU2/status/1610252584895258627)  2023-01-03T12:31Z [----] followers, [---] engagements


"@MitchellReed09 @OzmosiHealth 1) OBI-999 is an ADC from OBI-Pharma which made an announcement yesterday see link. 2) Their combination was with Keytruda from $MRK. $CKPT is not mentioned in the OBI Pharma announcement. 3) $SGYP ticker symbol does not exist. https://www.obipharma.com/news/news-2023-news/obi-pharma-announces-poster-presentations-at-aacr-2023-annual-meeting-for-obi-999-combination-synergy-with-checkpoint-inhibitor-as-well-as-globo-h-targeted-car-t-cell-immunotherapy/"  
[X Link](https://x.com/TOWiU2/status/1645724349763076097)  2023-04-11T09:43Z [----] followers, [---] engagements


"@webcrawler_vers @gj_tennis @jud_guy @PropThinker NerPharMa customer list: - Halaven (Eribulin EISAI) $ESAIY - Mavenclad (Cladribine Merck) $MRK.DE - Braftovi (Encorafenib Array Pfizer) $ARRY $PFE - Rozlytrek (Entrectinib Roche) $ROG.SW https://www.nerpharma.com/history/ https://www.nerpharma.com/history/"  
[X Link](https://x.com/TOWiU2/status/1689963887578218496)  2023-08-11T11:36Z [----] followers, [---] engagements


"$NAMS NEW PHASE [--] DATA: Topline results from our BROADWAY studyour largest Phase [--] clinical trial to dateevaluated obicetrapib our investigational CETP inhibitor in patients with ASCVD and/or HeFH who required additional lowering of their LDL-C levels. https://t.co/auKFfysQkk https://t.co/MHugI6MFjJ NEW PHASE [--] DATA: Topline results from our BROADWAY studyour largest Phase [--] clinical trial to dateevaluated obicetrapib our investigational CETP inhibitor in patients with ASCVD and/or HeFH who required additional lowering of their LDL-C levels. https://t.co/auKFfysQkk https://t.co/MHugI6MFjJ"  
[X Link](https://x.com/TOWiU2/status/1866462705348935979)  2024-12-10T12:39Z [----] followers, [---] engagements


"$NAMS [--] NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase [--] BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-announces-positive-topline-data-pivotal-1 https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-announces-positive-topline-data-pivotal-1"  
[X Link](https://x.com/TOWiU2/status/1866463688745754993)  2024-12-10T12:43Z [----] followers, [---] engagements


"Inozyme Pharma Reports First Quarter [----] Financial Results and Provides Business Highlights $inzy https://finance.yahoo.com/news/inozyme-pharma-reports-first-quarter-113000648.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/inozyme-pharma-reports-first-quarter-113000648.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"  
[X Link](https://x.com/TOWiU2/status/1922690552799121751)  2025-05-14T16:28Z [----] followers, [---] engagements


"BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma $INZY $BMRN https://finance.yahoo.com/news/biomarin-strengthens-enzyme-therapy-business-113000109.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/biomarin-strengthens-enzyme-therapy-business-113000109.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"  
[X Link](https://x.com/TOWiU2/status/1923372352441614842)  2025-05-16T13:37Z [----] followers, [---] engagements


"Regenxbio Fails To Best Sarepta's Elevidys With New Data for DMD Gene Therapy $srpt $rgnx https://www.biospace.com/drug-development/regenxbio-fails-to-best-sareptas-elevidys-with-new-data-for-dmd-gene-therapy https://www.biospace.com/drug-development/regenxbio-fails-to-best-sareptas-elevidys-with-new-data-for-dmd-gene-therapy"  
[X Link](https://x.com/TOWiU2/status/1931233396631503166)  2025-06-07T06:14Z [----] followers, [----] engagements


"@edcollins23 Thx again thats n = [--] for now. If we include $KROS it would be [--]. "In fact at an investor conference today CEO Jasbir Seehra acknowledged that the capital being held exceeds what is needed to fund the Company's current DMD program" https://www.prnewswire.com/news-releases/adar1-issues-statement-on-keros-therapeutics-troubling-2025-director-election-results-and-insufficient-capital-return-proposal-302476774.html"  
[X Link](https://x.com/TOWiU2/status/1932437630127309080)  2025-06-10T14:00Z [----] followers, [---] engagements


"$DCTH $IMCR $AURA $CSTL https://www.youtube.com/watchv=v3-gliNz33g https://www.youtube.com/watchv=v3-gliNz33g"  
[X Link](https://x.com/TOWiU2/status/1962809281138274310)  2025-09-02T09:26Z [----] followers, [----] engagements


"@ESG_Biotech @A_May_MD It seems that the existing $TARS sales team is pretty good at what they do. How high would the incremental sales be if $ABBV were involved"  
[X Link](https://x.com/TOWiU2/status/2007922265707679783)  2026-01-04T21:09Z [----] followers, [---] engagements


"This move: Promotion of Garijo & firing Udit Batra much more reflects what $MRK.DE so desperatly would like to be a serious competitor in the field of biopharma. Not so much reality e.g. the fact their real strenght resides rather in Life Sciences. Beln Garijo CEO Healthcare bei der #MerckKGaA ist nun stellvertretende Vorsitzende der Merck-Geschftsleitung und stellvertretender CEO. Life-Sciences-Chef Udit Batra verlsst Merck. https://t.co/UqewEuIxnx Beln Garijo CEO Healthcare bei der #MerckKGaA ist nun stellvertretende Vorsitzende der Merck-Geschftsleitung und stellvertretender CEO."  
[X Link](https://x.com/TOWiU2/status/1283319372937928704)  2020-07-15T08:35Z [----] followers, [--] engagements


"Biotech Pick & Shovel Plays: Interesting to see how $DHR outperforms its co-behemoth $TMO in [----] and how the dwarfs $SRT.DE & $RGEN are completely left behind. Will that be reversed"  
[X Link](https://x.com/TOWiU2/status/1408722813993852932)  2021-06-26T09:44Z [----] followers, [--] engagements


"@DonnaGSwain @RNAiAnalyst All: $tmo $dhr $srt.de $rgen. I think it's a [--] x blow: 1) Taking into account the possible loss of CV19 Vax & Booster production revenue. 2) All of them benefit greatly from the production of biologics. Now suddenly we see a small molecule again whose performance impresses"  
[X Link](https://x.com/TOWiU2/status/1457001514912948231)  2021-11-06T15:06Z [----] followers, [--] engagements


"@webcrawler_vers @gj_tennis @jud_guy @PropThinker $DCTH The NerPharMa Italy [---] was February [----] not June: "FDA investigators audited the NerPharMa S.r.l. - Nerviano Italy facility and issued inspectional observation (via FDA 483) on [--] Feb 2023." https://fdazilla.com/store/form483/3004762406-20230220 https://fdazilla.com/store/form483/3004762406-20230220"  
[X Link](https://x.com/TOWiU2/status/1689957334485712896)  2023-08-11T11:10Z [----] followers, [---] engagements


"New CEOs to join Merck KGaAs executive board $mrk.de Jean-Charles Wirth will become Life Science's CEO from [--] June [----] Danny Bar-Zohar will assume the role of healthcare CEO on the same date succeeding Peter Guenter who is retiring after an almost . https://finance.yahoo.com/news/ceos-join-merck-kgaa-executive-095814757.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/ceos-join-merck-kgaa-executive-095814757.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"  
[X Link](https://x.com/TOWiU2/status/1892158003278713264)  2025-02-19T10:23Z [----] followers, [---] engagements


"@stefaanbafort @Im_Specter Update: Form [--] filed on June [--]. Opaleye owns a total of [-------] $HROW shares. Down 1.3% from the [-------] at the end of the first quarter of [----] according to 13F"  
[X Link](https://x.com/TOWiU2/status/1950851716464746917)  2025-07-31T09:31Z [----] followers, [---] engagements


"It will be interesting to see if $SRPT provides guidance for [----] & [----] next Monday. Analysts expect a revenue decline from $2b in [----] to $1.6b in [----] but also anticipate that SRPT will return to profitability in [----] (consensus: $3.18 per share). https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announce-third-quarter-2025-financial https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announce-third-quarter-2025-financial"  
[X Link](https://x.com/TOWiU2/status/1984173303750128103)  2025-10-31T08:19Z [----] followers, [----] engagements


"$SRPT Announces 3rd Q [----] Financial Results & Recent Corporate Developments Including Completion of Its Confirmatory Study ESSENCE Net product revenues for the 3rd quarter [----] totaled $370.0M consisting of $238.5M of PMO & $131.5M of ELEVIDYS https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2025-financial https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2025-financial"  
[X Link](https://x.com/TOWiU2/status/1985456563029753934)  2025-11-03T21:18Z [----] followers, [----] engagements


"@TripleGateCaptl @Biomaven What you describe is already on the market from $BLCO its called Miebo. The differences are: a) $HROW Vevyes vehicle is a shorter semifluorinated alkane = perfluorobutylpentane then perfluorohexyloctane aka Miebo. b) Miebo will be a blockbuster but not OTC"  
[X Link](https://x.com/TOWiU2/status/1987154160484044970)  2025-11-08T13:44Z [----] followers, [---] engagements


"@stefaanbafort @Im_Specter Update: Form [--] filed on January 8th [----]. Opaleye owns a total of [-------] $HROW shares. Down 20k shares = 0.5% from the [-------] at the end of the third quarter of [----] according to 13F. https://whalewisdom.com/filer/opaleye-management-inc https://www.harrow.com/static-files/3a075333-3fe2-448d-9598-133589fbca54 https://whalewisdom.com/filer/opaleye-management-inc https://www.harrow.com/static-files/3a075333-3fe2-448d-9598-133589fbca54"  
[X Link](https://x.com/TOWiU2/status/2017953658487382056)  2026-02-01T13:30Z [----] followers, [---] engagements


""ImprimisRx Settles Pending Regulatory Matters and Voluntarily Exits California" = - agreed to an administrative fine of approx $157000 - exited the California market effective February [--] [----]. $HROW w continue to serve the CA market with its portfolio of branded products"  
[X Link](https://x.com/TOWiU2/status/2018301748364865857)  2026-02-02T12:33Z [----] followers, [----] engagements


"Today's announcement from $HROW uses many "On Track" "Underway" "Proceeding" etc to obscure/hide the message: "ImprimisRx exits California". https://www.harrow.com/news-releases/news-release-details/harrow-reaffirms-2025-full-year-revenue-guidance-270-280-million "ImprimisRx Settles Pending Regulatory Matters and Voluntarily Exits California" = - agreed to an administrative fine of approx $157000 - exited the California market effective February [--] [----]. $HROW w continue to serve the CA market with its portfolio of branded products."  
[X Link](https://x.com/TOWiU2/status/2018304550604615709)  2026-02-02T12:44Z [----] followers, [----] engagements


"$DHR $TMO $SRT.DE $RGEN Poll: Pick & Shovel Outperformer Period: 01/01/2021 - 12/31/2025 DHR TMO RGEN SRT.DE DHR TMO RGEN SRT.DE"  
[X Link](https://x.com/TOWiU2/status/1408729200111017986)  2021-06-26T10:09Z [----] followers, [--] engagements


"@SnupSnus @john_bresnahan 2/2) a) what about $dhr $tmo $srt.de $rgen b) $mrk.de is not on my list - as in fact I do fully agree with: c) $lonn.sw vs $sfnz.sw = 1/2) a) https://twitter.com/john_bresnahan/status/1487110005241356294 https://twitter.com/john_bresnahan/status/1487110005241356294"  
[X Link](https://x.com/TOWiU2/status/1487114571118747650)  2022-01-28T17:25Z [----] followers, [--] engagements


"Zealand Pharma announces Boehringer Ingelheim survodutide Phase [--] trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH with significant improvements in fibrosis via @YahooFinance $ZEAL.CO https://finance.yahoo.com/news/zealand-pharma-announces-boehringer-ingelheim-070600050.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/zealand-pharma-announces-boehringer-ingelheim-070600050.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"  
[X Link](https://x.com/TOWiU2/status/1762037892451365165)  2024-02-26T08:52Z [----] followers, [---] engagements


"https://www.rttnews.com/corpinfo/fdacalendar.aspxPageNum=4 https://www.rttnews.com/corpinfo/fdacalendar.aspxPageNum=4"  
[X Link](https://x.com/TOWiU2/status/1997615419562299850)  2025-12-07T10:33Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing